查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992949

抗風濕藥物市場：依藥物類別、給藥途徑、類型、疾病類型及通路分類－2026-2032年全球市場預測

Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年抗風濕藥物市場價值1,019.5億美元，預計到2026年將成長至1,077.1億美元，複合年成長率為5.89%，到2032年將達到1,522.8億美元。

主要市場統計數據
基準年 2025 1019.5億美元
預計年份：2026年 1077.1億美元
預測年份 2032 1522.8億美元
複合年成長率 (%) 5.89%

一個簡潔而具有戰略意義的框架，涵蓋了臨床、監管和商業性因素，定義了當前的抗風濕藥物市場環境和決策重點。

抗風濕藥物的治療模式錯綜複雜，涉及複雜的免疫學、不斷發展的治療方法以及不斷變化的醫療服務模式。本文概述了當前抗風濕藥物治療格局的關鍵臨床和商業性特徵，並指出了決策者應考慮的關鍵因素。此外，本文也重點闡述了緩解疾病藥物的創新、標靶生技藥品和小分子化合物的成熟，以及以患者為中心的診療路徑的日益普及，如何全面重塑臨床實踐和商業策略。

標靶治療、生物標記主導的精準醫療方法以及給藥方式的創新如何重新定義風濕病的臨床實踐和治療途徑。

抗風濕藥物領域正經歷一場變革，其驅動力來自科學突破、不斷發展的治療方法以及精準醫療與價值醫療的融合。免疫學和分子生物學的進步正在加速從廣譜抗發炎藥物轉變為標靶疾病修正治療的轉變，這些療法旨在改變疾病本身的進程，而不僅僅是控制症狀。這種轉變使得基於生物標記的患者篩選和伴隨診斷的開發對於最佳化臨床療效變得癒發重要。

評估美國在 2025 年實施的關稅調整對營運和供應鏈的累積影響以及產業相關人員採取的策略緩解措施。

2025年新關稅政策的實施帶來了一系列複雜的貿易和成本考量，將對研發供應鏈、生產投入和跨境分銷產生影響。這些關稅變化進一步促使各組織重新評估籌資策略，並考慮其對下游契約製造協議的影響。因此，製造商和採購團隊開始評估替代供應地點、多通路採購策略和近岸外包方案，以減輕跨境成本上升的影響。

根據對治療領域、作用機制、給藥途徑、適應症、產品類型和分銷管道的全面細分所獲得的洞察，制定有針對性的策略設計。

詳細的細分分析揭示了抗風濕藥物治療領域固有的臨床和商業性複雜性，為產品和組合策略提供了可靠的框架。藥物類別細分包括皮質類固醇、緩解疾病抗風濕藥（DMARDs）、非類固醇消炎劑（NSAIDs）和尿酸標靶療法，其中緩解疾病藥類別進一步細分為生物製劑DMARDs、傳統DMARDs和標靶合成DMARDs。在生物製劑DMARDs中，基於作用機制的亞群（例如B細胞抑制劑、白細胞介素抑制劑、T細胞共刺激調節劑和腫瘤壞死因子抑制劑）進一步區分，每種亞群對療效、安全性和市場進入都有其獨特的影響。

美洲、歐洲、中東和非洲以及亞太地區的臨床、監管和准入趨勢將如何影響差異化商業化和實證策略？

區域趨勢對抗風濕藥物領域的臨床導入、監管策略和商業性實施有顯著影響。美洲地區的特點是臨床研發活躍、高度重視以支付主導的價值論證，以及擁有成熟的風濕病診療中心。因此，美洲地區的商業化策略通常優先考慮高品質的比較證據和核准後真實世界研究，以促進醫保報銷談判和與專科藥房的合作。

整合開發能力、真實世界證據計畫、以病人為中心的創新以及加速推廣應用的策略夥伴關係，創造了競爭優勢。

抗風濕藥物領域的競爭格局由成熟的產品線、新一代生物製藥和新興標標靶治療組成，多家老牌製藥公司在多個治療領域發揮主導作用。這些公司不僅擁有深厚的免疫學專業知識，還具備全球研發能力、廣泛的企業發展以及與保險公司合作的豐富經驗。此外，許多專業生物製藥公司和創新計畫不斷推出挑戰現有治療模式的新機制，為策略夥伴關係創造了機會。

領導者應採取切實可行的、優先的行動，使臨床創新與支付方要求、供應彈性、病人參與和合作夥伴關係保持一致。

產業領導者應制定一份以行動為導向的挑戰清單，將科學創新與切實可行的市場准入計畫和業務永續營運結合。首先，應優先考慮臨床開發與支付方證據要求的一致性，將健康經濟學和結果研究納入 II 期和 III 期臨床試驗通訊協定，從而減少後期階段的准入阻力。儘早並持續地與關鍵意見領袖和支付相關人員溝通，將有助於完善終點指標，指導對比試驗設計，並支持反映真實臨床需求的報銷理由。

採用嚴謹、透明、多方面的研究途徑，結合相關人員訪談、臨床文獻綜述和專家檢驗，以產生可操作的策略見解。

本分析所依據的研究整合了定性和定量信息，並採用了一種多層次的調查方法，旨在確保研究結果的穩健性和可重複性。主要研究包括對臨床專業人員、行業高管、監管專家和支付方進行結構化訪談，以獲取關於治療方法創新、准入挑戰和營運限制的第一手觀點。這些直接研究結果輔以對同行評審的臨床研究、監管指導文件和公開的藥品申請文件的二次文獻綜述，從而對臨床和政策趨勢進行了多角度的檢驗。

策略整合強調需要產生綜合證據、供應彈性以及以社區為基礎的獲取策略，以實現不斷發展的抗風濕療法的潛力。

總之，由於治療方法創新、不斷變化的用藥環境以及日益複雜的供應鏈，抗風濕藥物生態系統正在經歷重大變化。從症狀管理轉向標靶緩解疾病，並以生物製藥和標靶合成藥物的進步為支撐，這既帶來了臨床機遇，也帶來了戰略挑戰。積極整合以支付方為中心的循證實踐、以患者為中心的服務模式以及穩健的運營策略的相關人員，將更有能力把科學進步轉化為可及且永續的治療方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗風濕藥物市場：依藥物類別分類

  • 皮質類固醇
  • 緩解疾病抗風濕藥物
    • 生物DMARD
      • B細胞抑制劑
      • 白細胞介素抑制劑
      • T細胞共刺激調節劑
      • 腫瘤壞死因子（TNF）抑制劑
    • 傳統DMARD
    • 標靶合成DMARD
  • 非類固醇消炎劑
  • 降尿酸藥物

第9章：抗風濕藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第10章：抗風濕藥物市場：依類型分類

  • 非處方藥
  • 處方藥

第11章：抗風濕藥物市場：依疾病類型分類

  • 僵直性脊椎炎
  • 黏液囊炎
  • 痛風
  • 幼年特發性關節炎
  • 骨關節炎
  • 骨質疏鬆症
  • 多發性肌痛
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 修格蘭氏症候群
  • 全身性紅斑性狼瘡
  • 全身性硬化症/硬皮症
  • 肌腱炎

第12章：抗風濕藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：抗風濕藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：抗風濕藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗風濕藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗風濕藥物市場

第17章：中國抗風濕藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • DeepCure
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ILTOO Pharma SAS
  • Johnson & Johnson Services Inc.
  • medac GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market was valued at USD 101.95 billion in 2025 and is projected to grow to USD 107.71 billion in 2026, with a CAGR of 5.89%, reaching USD 152.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 101.95 billion
Estimated Year [2026] USD 107.71 billion
Forecast Year [2032] USD 152.28 billion
CAGR (%) 5.89%

A concise and strategic framing of clinical, regulatory, and commercial drivers that define the contemporary anti-rheumatics environment and decision-making priorities

The anti-rheumatics therapeutic arena sits at the intersection of complex immunology, evolving therapeutic modalities, and shifting healthcare delivery paradigms. This introduction distills the essential clinical and commercial contours that define the current landscape while clarifying the critical drivers that decision-makers must consider. It foregrounds how innovation in disease-modifying agents, the maturation of targeted biologics and small molecules, and heightened patient-centric care pathways are collectively reshaping clinical practice and commercial strategies.

Beyond clinical innovation, regulatory expectations and payer scrutiny continue to influence development priorities and commercialization timelines. As stakeholders increasingly prioritize real-world evidence and cost-effectiveness alongside efficacy and safety, developers and payers must reconcile clinical value with sustainable access models. Consequently, the therapeutic environment demands cross-functional alignment among clinical development teams, health economics specialists, market access strategists, and commercial leaders to translate scientific advances into adoptable treatments.

Finally, the introduction highlights the imperative of agile strategy formulation. Organizations that operationalize robust evidence generation plans, engage early with key opinion leaders and payers, and deploy adaptive commercial approaches will be better positioned to convert scientific progress into meaningful patient outcomes and durable clinical adoption. This framing sets the stage for deeper analysis in subsequent sections that examine transformative shifts, policy impacts, segmentation dynamics, regional variation, competitive positioning, and practical recommendations for leaders.

How advances in targeted therapies, biomarker-driven precision approaches, and delivery innovations are redefining clinical practice and access for rheumatic diseases

The anti-rheumatics landscape is in the midst of transformative shifts driven by scientific breakthroughs, evolving therapeutic modalities, and the convergence of precision medicine with value-based care. Advances in immunology and molecular biology have accelerated the transition from broad-spectrum anti-inflammatories to targeted disease-modifying therapies that aim to alter disease trajectories rather than manage symptoms alone. This shift elevates the importance of biomarker-driven patient selection and the development of companion diagnostics to optimize clinical outcomes.

Concurrently, the therapeutic toolkit is diversifying. Biologic agents continue to mature alongside targeted synthetic disease-modifying therapies, and there is renewed interest in novel mechanisms such as B-cell modulation, interleukin signaling inhibitors, and co-stimulation pathway antagonists. These options, together with optimized small-molecule inhibitors, enable more personalized regimens and combination strategies. As clinical practice incorporates these options, payers and providers demand robust comparative effectiveness and long-term safety data to inform formularies and treatment algorithms.

In parallel, delivery and adherence innovations are reshaping how therapies are administered and experienced by patients. Injectable therapies now coexist with improved oral regimens and localized topical formulations, creating new considerations for patient preference, adherence, and health system logistics. Moreover, the digitalization of care pathways, including telehealth and remote monitoring, is enhancing chronic disease management while imposing new requirements for evidence demonstrating real-world benefit. Taken together, these transformative shifts create both opportunity and complexity for developers and healthcare systems seeking to deliver superior clinical outcomes while ensuring access and affordability.

Assessing the cumulative operational and supply chain consequences of United States tariff adjustments introduced in 2025 and strategic mitigations adopted by industry stakeholders

The implementation of new tariff policies in 2025 introduced a complex set of trade and cost considerations that have implications across research supply chains, manufacturing inputs, and cross-border distribution. These tariff changes amplified the need for organizations to reassess sourcing strategies for active pharmaceutical ingredients, bioprocessing supplies, and specialized packaging, and to consider the downstream impacts on contract manufacturing arrangements. As a consequence, manufacturers and procurement teams have begun to evaluate alternative supply hubs, multi-sourcing approaches, and nearshoring options to mitigate exposure to incremental cross-border costs.

In addition to procurement pressures, tariffs have influenced contract negotiation dynamics with third-party suppliers, prompting renewed emphasis on long-term agreements and cost-sharing provisions that stabilize input pricing. Regulatory filings and international clinical trial operations have also felt the effects, as logistics complexity and import-export compliance requirements impose additional administrative burdens and potential delays. These operational friction points underscore the importance of integrated supply chain visibility and proactive contingency planning.

Importantly, the tariff environment has not affected all stakeholders uniformly. Companies with integrated manufacturing footprints and established regional distribution networks have demonstrated greater resilience, whereas asset-light organizations that rely on single-source international suppliers have faced higher disruption risk. Consequently, strategic responses have included accelerating investments in regional manufacturing, strengthening supplier diversification, and enhancing scenario planning. Looking ahead, sustained attention to trade policy developments and adaptive procurement strategies will remain essential for preserving operational continuity and supporting reliable therapy availability.

Comprehensive segmentation-driven insights across therapeutic classes, mechanisms, administration routes, disease indications, product types, and distribution channels for targeted strategy design

Deep segmentation analysis reveals the clinical and commercial complexity inherent in the anti-rheumatics therapeutic area and provides a robust framework for product and portfolio strategy. Drug class distinctions encompass corticosteroids, disease-modifying anti-rheumatics drugs, nonsteroidal anti-inflammatory drugs, and uric acid-targeted therapies, with the disease-modifying category further disaggregated into biologic DMARDs, conventional DMARDs, and targeted synthetic DMARDs. Within biologic DMARDs, the landscape is nuanced by mechanism-of-action subgroups that include B-cell inhibitors, interleukin inhibitors, T-cell co-stimulation modulators, and tumor necrosis factor inhibitors, each carrying distinct efficacy, safety, and market access implications.

Route-of-administration segmentation differentiates injectable, oral, and topical modalities, a classification that informs adherence strategies, patient preference analysis, and distribution logistics. When considering product type, the distinction between over-the-counter and prescription-based therapies influences regulatory pathways, promotional frameworks, and payer interactions. Disease-type segmentation spans a wide clinical spectrum including ankylosing spondylitis, bursitis, gout, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis or scleroderma, and tendinitis, and this diversity necessitates tailored clinical development plans and targeted messaging to distinct clinical specialists.

Finally, distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies shape access strategies, patient journey mapping, and channel economics. By integrating these segmentation lenses, stakeholders can prioritize development investments, refine value propositions for payers and providers, and design patient support programs that align with both therapeutic modality and end-user preferences. This holistic segmentation approach supports more precise positioning, competitive differentiation, and evidence plans that reflect the heterogeneity of both disease and care delivery.

How regional clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated commercialization and evidence strategies

Regional dynamics exert a powerful influence on clinical adoption, regulatory approaches, and commercial execution in the anti-rheumatics domain. The Americas region has been characterized by robust clinical development activity, a strong emphasis on payer-driven value demonstration, and established centers of excellence for rheumatology care. As a result, commercialization strategies in the Americas often prioritize high-quality comparative evidence and post-authorization real-world studies that inform reimbursement negotiations and specialty pharmacy integration.

Europe, the Middle East and Africa presents a heterogeneous landscape where regulatory frameworks, health technology assessment processes, and reimbursement criteria vary significantly across jurisdictions. Stakeholders operating across this region must tailor evidence generation and access strategies to meet diverse national requirements, engage proactively with regional key opinion leaders, and navigate complex tendering and formulary processes. Collaboration with local clinical experts and early engagement with assessment bodies can accelerate reimbursement pathways and support uptake.

Asia-Pacific continues to evolve rapidly with varying levels of clinical infrastructure, regulatory sophistication, and payer maturity. Many markets in the region are increasing investments in biologic therapies while simultaneously expanding local manufacturing capabilities and regulatory pathways for biosimilars. Consequently, manufacturers should align regulatory submission strategies, pricing approaches, and patient support models with local market dynamics to ensure sustainable access and adoption. Across all regions, cross-border collaboration, localized evidence generation, and nuanced stakeholder engagement remain central to achieving durable clinical and commercial outcomes.

Competitive advantage is driven by integrated development capabilities, real-world evidence programs, patient support innovations, and strategic partnerships that accelerate adoption

Competitive positioning within the anti-rheumatics arena reflects a mix of legacy franchises, next-generation biologics, and emerging targeted therapies, with several established pharmaceutical companies holding leading roles across multiple therapeutic classes. These organizations pair deep immunology expertise with global development capabilities, broad commercial footprints, and extensive payer engagement experience. Moreover, a set of specialized biopharmaceutical firms and innovator programs continue to introduce novel mechanisms that challenge incumbent therapeutic paradigms and create opportunities for strategic partnerships.

In addition to product portfolios, competitive differentiation increasingly arises from integrated capabilities such as advanced manufacturing, real-world evidence generation, and patient support services that enhance adherence and long-term outcomes. Companies that invest in companion diagnostics, digital health solutions for chronic disease management, and robust pharmacovigilance systems achieve stronger alignment with provider and payer expectations. Strategic alliances, licensing agreements, and selective mergers and acquisitions remain pragmatic paths to complement internal capabilities and accelerate access to promising modalities.

Finally, corporate strategies that prioritize transparent outcomes data, constructive engagement with health technology assessment bodies, and proactive pricing and reimbursement dialogues tend to reduce commercialization friction. As competition intensifies, the ability to demonstrate compelling value across clinical, economic, and humanistic endpoints will determine which therapies achieve sustained adoption and which struggle to secure durable placement within therapeutic guidelines and payer formularies.

Practical and prioritized actions leaders should implement to align clinical innovation with payer requirements, supply resilience, patient engagement, and collaborative partnerships

Industry leaders should adopt an action-oriented agenda that aligns scientific innovation with pragmatic access planning and operational resilience. First, prioritize the alignment of clinical development with payer evidence requirements by embedding health economics and outcomes research into phase II and III protocols, thereby reducing later-stage access friction. Early and continuous engagement with key opinion leaders and payer stakeholders will refine endpoints, inform comparative trial design, and support reimbursement narratives that reflect real-world clinical priorities.

Second, strengthen supply chain resilience through strategic supplier diversification, regional manufacturing investments, and enhanced inventory visibility. These measures help mitigate tariff-related and geopolitical risks while preserving clinical trial continuity and commercial supply. Third, adopt patient-centric commercialization approaches that incorporate route-of-administration preferences, adherence support tools, and digital interventions to improve engagement and long-term outcomes. Tailored patient support programs can also reduce barriers to initiation and sustainment of complex regimens.

Fourth, pursue targeted partnerships that accelerate access to complementary capabilities, including diagnostic developers, specialty pharmacies, and digital health providers. Such collaborations can expand product value propositions and streamline care pathways. Finally, commit to transparent evidence sharing and proactive pricing dialogues with payers and providers to build trust and expedite inclusion in treatment guidelines and formularies. Together, these actions create a coherent strategic posture that balances innovation with access, operational stability, and enduring patient benefit.

A rigorous and transparent multi-method research approach that integrates stakeholder interviews, clinical literature review, and expert validation to produce actionable strategic insights

The research underpinning this analysis synthesized qualitative and quantitative inputs using a layered methodology designed to ensure robustness and reproducibility. Primary research included structured interviews with clinical specialists, industry executives, regulatory experts, and payers to capture first-hand perspectives on therapeutic innovation, access challenges, and operational constraints. These direct insights were complemented by secondary literature review of peer-reviewed clinical studies, regulatory guidance documents, and publicly available pharmaceutical filings to triangulate clinical and policy trends.

Data synthesis relied on thematic analysis to identify consistent signals across stakeholder interviews and document review, supplemented by case-based comparative assessments of therapeutic classes and regional regulatory pathways. Validation workshops with independent clinical experts and commercial leaders provided further scrutiny of key findings and ensured that conclusions reflect practical realities faced by developers and healthcare systems. Throughout the process, careful attention to methodological transparency, bias mitigation, and traceability of sources reinforced the credibility of insights.

Finally, segmentation-driven analyses were performed to align evidence needs with therapeutic modality, route of administration, indication, and distribution channel considerations. This approach supported nuanced recommendations that are actionable across both global strategy and local implementation contexts, while preserving clarity about the assumptions and limitations inherent in qualitative research synthesis.

Strategic synthesis emphasizing the need for integrated evidence generation, supply resilience, and localized access strategies to realize the promise of evolving anti-rheumatics therapies

In conclusion, the anti-rheumatics ecosystem is undergoing substantive change driven by therapeutic innovation, evolving access dynamics, and supply chain complexities. The transition from symptom management toward targeted disease modification, supported by advances in biologics and targeted synthetic agents, presents both clinical promise and strategic complexity. Stakeholders that proactively integrate payer-focused evidence generation, patient-centric delivery models, and resilient operational strategies will be best positioned to translate scientific advances into accessible and sustainable therapeutic options.

Moreover, regional heterogeneity in regulatory expectations and reimbursement mechanisms requires tailored approaches that balance global strategy with local execution. Strategic partnerships, investments in manufacturing and supply chain diversification, and transparent engagement with payers and clinical communities will materially influence the trajectory of adoption. Ultimately, the combination of rigorous clinical evidence, robust real-world data, and collaborative commercialization models offers the most effective pathway to improve outcomes for patients living with rheumatic diseases while ensuring the viability of innovative therapies in complex healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Rheumatics Market, by Drug Class

  • 8.1. Corticosteroids
  • 8.2. Disease Modifying Anti-rheumatics Drugs
    • 8.2.1. Biologic DMARDs
      • 8.2.1.1. B-cell Inhibitors
      • 8.2.1.2. Interleukin Inhibitors
      • 8.2.1.3. T-cell Co-stimulation Modulators
      • 8.2.1.4. Tumor Necrosis Factor (TNF) Inhibitors
    • 8.2.2. Conventional DMARDs
    • 8.2.3. Targeted Synthetic DMARDs
  • 8.3. Nonsteroidal Anti-inflammatory Drugs
  • 8.4. Uric Acid Drugs

9. Anti-Rheumatics Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Anti-Rheumatics Market, by Type

  • 10.1. Over-the-Counter Drugs
  • 10.2. Prescription-Based Drugs

11. Anti-Rheumatics Market, by Disease Type

  • 11.1. Ankylosing Spondylitis
  • 11.2. Bursitis
  • 11.3. Gout
  • 11.4. Juvenile Idiopathic Arthritis
  • 11.5. Osteoarthritis
  • 11.6. Osteoporosis
  • 11.7. Polymyalgia Rheumatica
  • 11.8. Psoriatic Arthritis
  • 11.9. Rheumatoid Arthritis
  • 11.10. Sjogren's Syndrome
  • 11.11. Systemic Lupus Erythematosus
  • 11.12. Systemic Sclerosis/Scleroderma
  • 11.13. Tendinitis

12. Anti-Rheumatics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Rheumatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-Rheumatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Rheumatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-Rheumatics Market

17. China Anti-Rheumatics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alvotech
  • 18.7. Amgen Inc.
  • 18.8. ANI Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Bayer AG
  • 18.11. Biogen Inc.
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. C. H. Boehringer Sohn AG & Co. KG
  • 18.14. DeepCure
  • 18.15. Eisai Co., Ltd.
  • 18.16. Eli Lilly and Company
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. Fresenius Kabi AG
  • 18.19. Galapagos NV
  • 18.20. Gilead Sciences, Inc.
  • 18.21. GlaxoSmithKline PLC
  • 18.22. ILTOO Pharma SAS
  • 18.23. Johnson & Johnson Services Inc.
  • 18.24. medac GmbH
  • 18.25. Merck & Co., Inc.
  • 18.26. Novartis AG
  • 18.27. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • 18.28. Pfizer, Inc.
  • 18.29. Regeneron Pharmaceuticals, Inc.
  • 18.30. Sanofi SA
  • 18.31. Takeda Pharmaceutical Company Limited
  • 18.32. Teva Pharmaceutical Industries Ltd.
  • 18.33. UCB S.A.
  • 18.34. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)